Pharmacological management of unipolar depression

Acta Psychiatrica Scandinavica

Volumn 127, Issue SUPPL. 443, 2013, Pages 6-23

  Malhi, G S ^a,b   Hitching, R ^a,b   Berk, M ^c,d,e,f,g   Boyce, P ^b   Porter, R ^h   Fritz, K ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^f FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^g THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^h UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Antidepressants; Clinical practice guidelines; Major depressive disorder; Recommendations; Treatment algorithm

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; ATOMOXETINE; CLOMIPRAMINE; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; LITHIUM; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PAROXETINE; REBOXETINE; RISPERIDONE; SEROTONIN ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPLE REUPTAKE INHIBITOR; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ALGORITHM; ANXIETY DISORDER; ARTICLE; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONVALESCENCE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; ELECTROCONVULSIVE THERAPY; FAMILY; FATIGUE; FRIEND; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HUMAN; INSOMNIA; LIFESTYLE; LOW DRUG DOSE; MAJOR DEPRESSION; MEDLINE; MELANCHOLIA; MONOTHERAPY; PAIN; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REMISSION; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOCIAL ASPECT; TREATMENT RESPONSE; TREMOR; XEROSTOMIA; DRUG MONITORING; EVIDENCE BASED PRACTICE; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; METHODOLOGY; PATIENT REFERRAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG MONITORING; EVIDENCE-BASED PRACTICE; HUMANS; MEDICATION ADHERENCE; MEDICATION THERAPY MANAGEMENT; PRACTICE GUIDELINES AS TOPIC; REFERRAL AND CONSULTATION; TREATMENT OUTCOME;

EID: 84886742429     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12122     Document Type: Article

References (135)

1. Malhi GS, Adams D, Porter R et al. Clinical practice recommendations for depression. Acta Psychiatr Scand 2009;119(Suppl. 439):8-26.
2. Malhi GS, Hitching R, Coulston CM, Boyce P, Porter R, Fritz K. Preface: individualized management of unipolar depression. Acta Psychiatr Scand 2013;127(Suppl. 443):1-5.
3. Lampe L, Coulston CM, Berk L. Psychological management of unipolar depression. Acta Psychiatr Scand 2013;127(Suppl. 443):24-37
4. Berk M, Sarris J, Coulson CE, Jacka FN. Lifestyle management of unipolar depression. Acta Psychiatr Scand 2013;127(Suppl. 443):38-54.
5. Serretti A, Drago A, Spina E. Pharmacogenomics of Depression. Adv Biol Psychiatry 2010;25:58-74.
6. Bech P. The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure. Acta Psychiatr Scand 2002;106:252-264.
7. McIntyre RS, Konarski JZ, Kennedy SH, Dickens SE, Bagby RM. Measuring depressive symptoms in the naturalistic primary-care setting. Int J Clin Pract 2007;61:1278-1282.
8. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008;63:424-434.
9. Taylor MA, Fink M. Restoring melancholia in the classification of mood disorders. J Affect Disord 2008;105:1-14.
10. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005;330:385.
11. Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006;26:203-207.
12. Hansen DG, Vach W, Rosholm J, Sondergaard J, Gram LF, Kragstrup J. Early discontinuation of antidepressants in general practice: association with patient and prescriber characteristics. Fam Pract 2004;21:623-629.
13. Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression int he United States. Am J Psychiatry 2006;163:101-108.
14. Trivedi MH, Rush AJ, Gaynes BN et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology 2007;32:2479-2489.
15. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58:19-36.
16. Noël PH, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000;132:743-756.
17. Arroll B, Macgillivray S, Ogston S et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 2005;3:449-456.
18. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009;25:161-175.
19. Cipriani A, Furukawa TA, Geddes JR et al. Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. J Clin Psychiatry 2008;69:1732-1742.
20. Schueler YB, Koesters M, Wieseler B et al. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 2011;123:247-265.
21. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-758.
22. Eyding D, Lelgemann M, Grouven U et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. Br Med J 2010;341:c4737.
23. Preskorn SH, Borges-Gonzalez S, Flockhart D. Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part II. J Psychiatr Pract 2006;12:312-316.
24. Quera-Salva MA, Lemoine P, Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol 2010;25:222-229.
25. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 2005;66:148-158.
26. Stassen HH, Kuny S, Hell D. The speech analysis approach to determining onset of improvement under antidepressants. Eur Neuropsychopharmacol 1998;8:303-310.
27. Stassen HH, Angst J, Delini-Stula A. Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement. Pharmacopsychiatry 1999;32:56-60.
28. Rush AJ. STAR*D: what have we learned? Am J Psychiatry 2007;164:201-204.
29. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005;255:387-400.
30. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-336.
31. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16:54S-61S.
32. Parikh SV, Segal ZV, Grigoriadis S et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Clin Psychopharmacol 2009;117:S15-S25.
33. Kennedy SH, Milev R, Giacobbe P et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of depressive disorder in adults. IV. Neurostimulation therapies. J Affect Disord 2009;117:S44-S53.
34. Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology 2002;161:143-151.
35. Henricus GR, Huyser J, Swinkles JA, Schene AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder. Br J Psychiatry 2006;189:309-316.
36. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry 2006;189:309-316.
37. Debonnel G, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Blier P. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 2007;10:51-61.
38. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006;23:364-372.
39. Horgan D, Dodd S, Berk M. A survey of combination antidepressant use in Australia. Australas Psychiatry 2007;15:26-29.
40. Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010;167:281-288.
41. Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand 2012;125:342-348.
42. Rush AJ. Combining antidepressant medications: a good idea? Am J Psychiatry 2010;167:241-243.
43. Malhi GS, Ng F, Berk M. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. Aust N Z J Psychiatry 2008;42:346-349.
44. Rocha FL, Fuzikawa C, Riera R, Hara C. Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol 2012;32:278-281.
45. Blier P, Gobbi G, Turcotte JE et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009;19:457-465.
46. Altshuler LL, Bauer M, Frye MA et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001;158:1617-1622.
47. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996;53:842-848.
48. Rosenthal LJ, Goldner WS, O'Reardon JP. T3 augmentation in major depressive disorder: safety considerations. Am J Psychiatry 2011;168:1035-1040.
49. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007;68:934-940.
50. Bauer M, Bschor T, Kunz D, Berghofer A, Strohle A, Muller-Oerlinghausen B. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000;157:1429-1435.
51. Berghofer A, Grof P, Muller-Oerlinghausen B. Recommendations for the safe use of lithium. In: Bauer M, Grof P, Muller-Oerlinghausen B, eds. Lithium in neuropsychiatry: the comprehensive guide. London: Informa healthcare, 2006:443-464.
52. Bschor T, Kunz D, Bauer M. Successful lithium augmentation: how long should lithium be continued? XI World Congress of Psychiatry; 6-11 August 1999; Paper presented at Hamburg, Germany, 2009.
53. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007;68:826-831.
54. Philip NS, Carpenter LL, Tyrka AR, Price LH. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. J Psychiatr Pract 2008;14:34-44.
55. Berman RM, Marcus RN, Swanink R et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-853.
56. Marcus RN, McQuade RD, Carson WH et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:156-165.
57. Nakajima S, Uchida H, Suzuki T et al. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: A randomized open-label trial. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1983-1989.
58. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006;67:1836-1855.
59. Souery D, Serretti A, Calati R et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol 2011;31:512-516.
60. Rush AJ, Trivedi MH, Wisniewski SR et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242.
61. Pagnin D, Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT 2004;20:13-20.
62. Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med 2007;357:1939-1945.
63. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003;361:799-808.
64. Shapira B, Tubi N, Lerer B. Balancing speed of response to ECT in major depression and adverse cognitive effects: role of treatment schedule. J ECT 2000;16:97-109.
65. Ottosson J-O, Odeberg H. Evidence-based electroconvulsive therapy. Acta Psychiatr Scand 2012;125:177-184.
66. Sackeim HA, Dillingham EM, Prudic J et al. Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects. Arch Gen Psychiatry 2009;66:729-737.
67. Kellner CH, Knapp RG, Petrides G et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006;63:1337-1344.
68. Petrides G, Fink M, Husain MM et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT 2001;17:244-253.
69. Prudic J, Haskett RF, Mulsant B et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 1996;153:985-992.
70. Rasmussen KG, Stevens SR, Kung S, Mohan A. Melancholic symptoms as assessed by the Hamilton Depression Rating Scale and outcomes with and without electroconvulsive therapy on an in-patient mood disorders unit. Acta Neuropsychiatr 2010;22:21-25.
71. Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994;45:444-450.
72. Yonkers KA, Wisner KL, Stewart DE et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009;31:403-413.
73. Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 2010;44:978-996.
74. Huang M-l, Luo B-y, Hu J-b et al. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial. Aust N Z J Psychiatry 2012;46:257-264.
75. Lozano AM, Mayberg HS, Giacobbe P, Hamani C, Craddock RC, Kennedy SH. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2008;64:461-467.
76. Kennedy SH, Giacobbe P, Rizvi SJ et al. Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry 2011;168:502-510.
77. Blomstedt P, Sjöberg RL, Hansson M, Bodlund O, Hariz MI. Deep brain stimulation in the treatment of depression. Acta Psychiatr Scand 2011;123:4-11.
78. Lewis CM, Ng MY, Butler AW et al. Genome-wide association study of major recurrent depression in the U.K. population. Am J Psychiatry 2010;167:949-957.
79. Uher R, Perroud N, Ng MY et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010;167:555-564.
80. Garriock HA, Tanowitz M, Kraft JB et al. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry 2010;167:565-573.
81. Duncan LE, Hutchison KE, Carey G, Craighead WE. Variation in brain-derived neurotrophic factor (BDNF) gene is associated with symptoms of depression. J Affect Disord 2009;115:215-219.
82. Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol 2010;70:289-297.
83. Chen L, Lawlor DA, Lewis SJ et al. Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2008;147B:814-821.
84. Uher R, Caspi A, Houts R et al. Serotonin transporter gene moderates childhood maltreatment's effects on persistent but not single-episode depression: replications and implications for resolving inconsistent results. J Affect Disord 2011;135:56-65.
85. Risch NHRLT et al. Interaction between the serotonin transporter gene (5-httlpr), stressful life events, and risk of depression: a meta-analysis. JAMA 2009;301:2462-2471.
86. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry 1996;168:17-30.
87. Fava M, Rush AJ, Alpert JE et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008;165:342-351.
88. Fava M, Alpert JE, Carmin CN et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med 2004;34:1299-1308.
89. Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression: meta-analysis of published studies. Br J Psychiatry 2006;188:13-20.
90. Rief W, Trenkamp S, Auer C, Fichter MM. Cognitive behavior therapy in panic disorder and comorbid major depression. Psychother Psychosom 2000;69:70-78.
91. Fiedorowicz JG, Endicott J, Leon AC, Solomon DA, Keller MB, Coryell WH. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry 2011;168:40-48.
92. Coryell W, Endicott J, Maser JD, Keller MB, Leon AC, Akiskal HS. Long-term stability of polarity distinctions in the affective disorders. Am J Psychiatry 1995;152:385-390.
93. Angst J, Cui L, Swendsen J et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry 2010;167:1194-1201.
94. Akiskal HS, Walker P, Puzantian VR, King D, Rosenthal TL, Dranon M. Bipolar outcome in the course of depressive illness. Phenomenologic, familial, and pharmacologic predictors J Affect Disord 1983;5:115-128.
95. Angst J, Sellaro R, Stassen HH, Gamma A. Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. J Affect Disord 2005;84:149-157.
96. Beesdo K, Hofler M, Leibenluft E, Lieb R, Bauer M, Pfennig A. Mood episodes and mood disorders: patterns of incidence and conversion in the first three decades of life. Bipolar Disord 2009;11:637-649.
97. Coryell W, Endicott J, Maser JD, Keller MB, Leon A, HS A. Long-term stability of polarity distinctions in the affective disorders. Am J Psychiatry 1995;152:385-390.
98. Strober M, Carlson G. Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation. Arch Gen Psychiatry 1982;39:549-555.
99. Geller B, Zimerman B, Williams M, Bolhofner K, Craney JL. Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder. Am J Psychiatry 2001;158:125-127.
100. Geddes JR, Carney SM, Davies C et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-661.
101. Reynolds CF 3rd, Dew MA, Pollock BG et al. Maintenance treatment of major depression in old age. N Engl J Med 2006;354:1130-1138.
102. Hansen DG, Gaynes BN, Thieda P et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 2008;59:1121-1130.
103. Holma IAK, Holma KM, Melartin TK, Rytsälä HJ, Isometsä ET. A 5-year prospective study of predictors for disability pension among patients with major depressive disorder. Acta Psychiatr Scand 2012;125:325-334.
104. Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998;5:293-306.
105. Papakostas GI, Perlis RH, Seifert C, Fava M. Antidepressant dose reduction and the risk of relapse in major depressive disorder. Psychother Psychosom 2007;76:266-270.
106. Belsher G, Costello CG. Relapse after recovery from unipolar depression: a critical review. Psychol Bull 1988;104:84-96.
107. Chong WW, Aslani P, Chen TF. Effectiveness of interventions to improve antidepressant medication adherence: a systematic review. Int J Clin Pract 2011;65:954-975.
108. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS drugs 2010;24:479-499.
109. Montejo AL, Prieto N, Terleira A et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol 2010;24:111-120.
110. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder. Arlington, VA: American Psychiatric Association, 2010.
111. University of Michigan Health System. Guidelines for clinical care: depression. Ann Arbor, MI: University of Michigan Health System, 2005.
112. American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000;157(Suppl. 4):1-45.
113. Wu C-H, Farley JF, Gaynes BN. The association between antidepressant dosage titration and medication adherence among patients with depression. Depress Anxiety 2012;29:506-514.
114. Berra C, Torta R. Therapeutic rationale of antidepressant use in the elderly. Arch Gerontol Geriatr 2007;44:83-90.
115. Amodeo L, Castelli L, Leombruni P, Cipriani D, Biancofiore A, Torta R. Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study. Support Care Cancer 2012;20:375-384.
116. de la Torre BR, Dreher J, Malevany L et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001;23:435-440.
117. Whitrayer VG, Dunner DL, Kornstein SG et al. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry 2007;68:1921-1930.
118. Sjöholm L, Lavebratt C, Forsell Y. A multifactorial developmental model for the etiology of major depression in a population-based sample. J Affect Disord 2009;113:66-76.
119. Wade TD, Kendler KS. The relationship between social support and major depression: cross-sectional, longitudinal, and genetic perspectives. J Nerv Ment Dis 2000;188:251-258.
120. Katzman MA, Tricco AC, McIntosh D et al. Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. J Clin Psychiatry 2007;68:1845-1859.
121. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985;46:53-58.
122. Feighner JP, Boyer WF. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scand 1989;80(Suppl. 350):125-129.
123. Lydiard RB, Laird LK, Morton WA Jr et al. Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull 1989;25:68-70.
124. Reimherr FW, Chouinard G, Cohn CK et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990;51(Suppl B):18-27.
125. Doogan DP, Langdon CJ. A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol 1994;9:95-100.
126. Muijen M, Roy D, Silverstone T, Mehmet A, Christie M. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand 1988;78:384-390.
127. Kiev A. A double-blind, placebo-controlled study of paroxetine in depressed outpatients. J Clin Psychiatry 1992;53(Suppl.):27-29.
128. Heiligenstein JH, Tollefson GD, Faries DE. A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia. Int Clin Psychopharmacol 1993;8:247-251.
129. Versiani MMD, Amin MMF, Chouinard GMFF. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000;20:28-34.
130. Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol 2002;22:393-399.
131. Papakostas GI, Nelson JC, Kasper S, Moller HJ. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Neuropsychopharmacol 2008;18:122-127.
132. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007;62:1217-1227.
133. Rickels K, Schweizer E, Clary C, Fox I, Weise C. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994;164:802-805.
134. Fabre L, Birkhimer LJ, Zaborny BA, Wong LF, Kapik BM. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. Int Clin Psychopharmacol 1996;11:119-127.
135. Cohn CK, Robinson DS, Roberts DL, Schwiderski UE, O'Brien K, Ieni JR. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 1996;57(Suppl. 2):15-18.